Testing an Education Program for Blood Sugar Control in Type 2 Diabetes
Tests the Ask Me 3® education program in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Glycemic Control and the Ask Me 3® Educational Program
Key facts
- Where
- San Nicolás de los Garza, MexicoSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who are cared for at the Metabolic Clinic of Hospital Clínica Nova. It tests an educational program, compared with standard care alone.
- Age
- 18 years or older, up to 80 years.
- Sex
- Men and women can join.
- Disease stage
- Confirmed type 2 diabetes mellitus, diagnosed by the institution's clinical practice guidelines.
Main reasons for not taking part
- Pregnant women
- Autoimmune, immunological or cancer-related conditions
- Palliative care
- Cognitive or psychiatric conditions that stop a person giving informed consent alone (for example delirium or schizophrenia)
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07678671, who can take part
Where in Mexico
- Hospital Clinica Nova de MonterreySan Nicolás de los Garza, MexicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Maria Elena Romero Ibarguengoitia
- Trial code
- NCT07678671
- Record updated
- 17 September 2026
- Original description
The goal of this clinical trial is to determine whether the Ask Me 3® educational program improves glycemic control in adults with type 2 diabetes mellitus receiving care at a metabolic clinic. The main questions it aims to answer are:Read full original descriptionShow less
Difference in Glycemic Control Among Patients With Type 2 Diabetes Mellitus Receiving the Ask Me 3® Educational Program: A 3-Month Follow-Up Study
The goal of this clinical trial is to determine whether the Ask Me 3® educational program improves glycemic control in adults with type 2 diabetes mellitus receiving care at a metabolic clinic. The main questions it aims to answer are:
Does participation in the Ask Me 3® educational program improve glycated hemoglobin (HbA1c) and fasting plasma glucose levels after a 3-month follow-up?
Researchers will compare participants who receive the Ask Me 3® educational program with those who receive standard medical care alone to determine whether the educational intervention improves glycemic control.
Participants will:
Provide written informed consent and undergo eligibility assessment. Be randomly assigned to either the intervention group or the control group. Complete baseline assessments, including demographic information, anthropometric measurements, medical history, dietary habits, physical activity, diabetes education, and nutritional counseling history.
Have baseline HbA1c and fasting plasma glucose values collected from their medical records.
Receive either the Ask Me 3® educational program (intervention group) or standard care (control group).
Attend routine follow-up visits over a 3-month period. Complete a final evaluation, including repeat clinical measurements and collection of HbA1c and fasting plasma glucose values to assess changes in glycemic control.
Inclusion: Adults aged 18 years or older; Beneficiaries of Hospital Clínica Nova; Male and female participants; Confirmed diagnosis of type 2 diabetes mellitus according to the institution's established clinical practice guidelines; Patients receiving care at the Metabolic Clinic.
Exclusion: Patients receiving palliative care; Patients with autoimmune, immunological, or oncological comorbidities; Patients with cognitive or psychiatric conditions that impair their ability to provide informed consent independently (e.g., delirium, schizophrenia, or similar conditions); Pregnant women.